FDA Announces Nationwide Recall of Nearly 90,000 Bottles of Children’s Ibuprofen Oral Suspension
The U.S. Food and Drug Administration has posted a nationwide Class II recall of nearly 90,000 bottles of Children’s Ibuprofen Oral Suspension after the manufacturer, Strides Pharma, received complaints of a "gel‑like mass and black particles" in some bottles. The liquid ibuprofen, a berry‑flavored pain and fever reducer for children ages 2 to 11, is manufactured in India by Strides for Taro Pharmaceuticals and was distributed across the United States. Class II status means exposure could cause temporary or medically reversible adverse health consequences, according to FDA criteria, though the agency has not reported any confirmed injuries tied to the contamination so far. Parents are being urged to check labels for the recalled product, identified under FDA recall number D‑0390‑2026, and to stop using any affected bottles pending further guidance from the company or regulators. The case underscores recurring quality‑control concerns around some foreign‑manufactured generics and over‑the‑counter medicines used widely by U.S. families, especially for children.
📌 Key Facts
- Nearly 90,000 bottles of Children’s Ibuprofen Oral Suspension are under recall in the U.S.
- Manufacturer Strides Pharma initiated the recall on March 2, 2026 after reports of a gel‑like mass and black particles in some bottles.
- The FDA classified it as a Class II recall, recall number D‑0390‑2026, indicating potential temporary or medically reversible adverse health effects.
📊 Relevant Data
From 2012 to 2023, the FDA documented 15,710 drug recall observations, with an average of 330 drug recalls initiated each year, showing an increasing trend.
A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023 — ResearchGate
Indian pharmaceutical companies, such as Sun Pharma, Cipla, Glenmark, and Zydus, have initiated multiple recalls of drugs in the US market from 2020 to 2026 due to manufacturing issues like contamination, potency deviations, and sterility concerns.
USFDA Recall of Indian Generic Drug Products: An In-Depth Analysis of Manufacturing Deficiencies, Regulatory Enforcement, and Risk Mitigation Approaches — International Journal of Pharmaceutical Sciences
Minority children in the US are less likely to receive adequate pain management compared to White children; for example, Black and Hispanic children are less likely to receive opioids for acute pain in emergency departments.
Racial and Ethnic Disparities in Pain Management of Children With Limb Fractures or Suspected Appendicitis in 3 US Pediatric Emergency Departments — PMC (PubMed Central)
Reported adverse drug reactions related to antipyretics like ibuprofen in children have increased, linked to rising usage, with data from 2015-2025 showing a marked rise.
Adverse reactions to acetaminophen and ibuprofen in pediatric pharmacovigilance: a retrospective analysis of the French pharmacovigilance database from 2015 to 2025 — PMC (PubMed Central)
📰 Source Timeline (1)
Follow how coverage of this story developed over time